BCL2L1 and cancer: Collectively, these observations challenge the notion that BH3 senolytic efficacy requires a primed, apoptotic-competent mitochondrial state and highlight the pivotal, transversal role of BCL-xL in preserving mitochondrial integrity of TIS cancer cells [92, 93], independent of the senescence-inducing therapeutic, stable or transient acquisition of senescence, or the underlying genetic context.